Advice

in the absence of a submission from the holder of the marketing authorisation:

vedolizumab (Entyvio®) is not recommended for use within NHSScotland.

Indication under review: treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice615KB (PDF)

Download

Medicine details

Medicine name:
vedolizumab (Entyvio)
SMC ID:
SMC2506
Indication:

Treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy

Pharmaceutical company
Takeda UK Ltd
BNF chapter
Gastro-intestinal system
Submission type
Non submission
Status
Not recommended
Date advice published
11 July 2022